Recent analyses have shown a stark imbalance in the distribution and access to renal cell carcinoma (RCC) clinical trials, with the studies conducted heavily skewed toward high-income countries.

Cameron Sperance is the former senior hotels reporter at TPG. His expertise includes branding, travel data, destinations and loyalty programs. The cards we feature here are from partners who ...

After the patient begins to present worsening lower back pain, a CT scan shows lytic lesions in her thoracic spine and rounded lesion in both lungs. A biopsy of the lung lesion confirms clear cell ...

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification. The phase 3 COSMIC-313 trial evaluated Cabometyx ...

“To add to the complexity is the issue of intratumoral heterogeneity, where some clones may develop these resistance mechanisms and lose response over time or become resistant, while other clones will ...

Discover 6 cozy hotels near America’s most iconic national parks for National Park Week 2025. Relax in style near Yellowstone, Arches, Rocky Mountains and more.

Two high-profile freehold unbranded hotels in central London have been brought to market with a combined price of over £110m.

Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

A phase 2 study showed a 93.3% objective response rate for lenvatinib and tislelizumab in FH-RCC patients, with a 20% complete response rate. FH-RCC is driven by FH gene mutations, leading to ...

RCC trials are predominantly in high-income countries, limiting access for lower-income patients and affecting global treatment strategies. Minority groups, especially Black and Hispanic ...

The 1.34 mg dose of Fotivda shows greater antitumor activity than the 0.89 mg dose in RCC patients, with similar hypertension incidence. Higher Fotivda exposure correlates with improved ...

Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone. Nivolumab (Opdivo) plus cabozantinib ...